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Introduction
Micronuclei (MNs) are small nuclear bodies that are formed in 
dividing cells but are not part of the nucleus. Therefore, MNs 
can only be found in cells that have undergone nuclear division 
at least once and appear as small extranuclear bodies. When 
two daughter nuclei are formed during cell division, these 
bodies are placed into a smaller nucleus that is not part of the 
main nuclei, hence the term “micronuclei.”1 Once the MNs are 
formed, the cell has several different response options. MNs 
can remain within the cell, if they have functional DNA, as 
separate entities or be reabsorbed into the main nucleus. If the 
DNA is nonfunctional, the MNs may be expelled from the cell 
or the whole cell may be destroyed through apoptosis. Because 
MNs can be expelled from the cell, they can be used as a mech-
anism to remove extra chromosomes from the cell.1
MNs can form spontaneously or they can be induced by 
mutagens. Some spontaneous MNs are actually beneficial to 
the organism. An example is in the mouse cerebral cortex, 
wherein MN formation adds diversity to the nervous system.1 
However, a large majority of MNs are caused by mutagens 
and may play a role in carcinogenesis. Depending on the fate 
of the MN, the result could be a variety of different DNA 
and chromosome cell contents. This variety could result in 
an accumulation of DNA changes and instability that could 
result in cancer.1 Several studies have shown that higher MN 
counts result in a higher risk of cancer in the future.1 Thus, 
using the cytokinesis-block micronucleus (CBMN) assay as 
a risk assessment tool for cancer has potential clinical ben-
efits. Further, combining CBMN with other high-throughput 
technologies such as gene expression and methylation analyses 
may help identify factors related to micronucleation.
Quantifying MNs in patient samples has been shown to 
be a good measure of genetic damage. MN scoring, ie, count-
ing the number of MNs present in a sample, is a popular tool 
for testing genotoxicity mostly because of its simplicity, accu-
racy, applicability to different cell types, and ease of automa-
tion. Cancer cells show a loss of genetic control, which can be 
caused by DNA damage; so, they are good candidates for MN 
testing. The CBMN assay has successfully been used and vali-
dated to score MNs. The CBMN assay uses cytochalasin-B, 
which stops cells from performing cytokinesis but does not 
stop nuclear division, giving rise to cells that are binucleated.2,3 
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Furthermore, the Organisation for Economic Co-operation 
and Development has developed a set of guidelines for run-
ning the CBMN assay to obtain the most consistent and reli-
able results.1
Guidelines for the process of scoring MNs have been 
presented by the HUman MicroNucleus (HUMN) project. 
This is an international collaborative project aimed at improv-
ing the application of the CBMN assay. One of the main goals 
of the HUMN project is to identify methodological variables 
in the scoring of the assay to minimize confounding effects.4 
The HUMN project compiled a list of 6583 subjects from 25 
laboratories in 16 countries and looked at background MN 
frequency using the CBMN assay. The goal of the study was to 
identify variables that affect the background MN frequency. 
Scoring criteria were found to account for 47% of the observed 
variability; thus, standardized scoring criteria were developed 
and described by Fenech et al.4 The guideline includes scoring 
2000 cells to accurately estimate MN frequency.
Because these guidelines were developed for assay perfor-
mance, they do not address how to statistically analyze the data 
generated by the assay. This has led to the application of various 
statistical methods that may render different interpretations and 
conclusions. In a review article examining analytical methods, 
Ceppi et al.5 reviewed 63 studies that statistically analyzed MN 
data and developed recommendations for selecting an appropri-
ate analytical method. The review included studies that applied 
both parametric and nonparametric tests. The nonparamet-
ric tests included Kruskal–Wallis, Friedman, Wilcoxon, and 
Mann–Whitney U-tests. Although these tests do not require an 
underlying distributional assumption, they are unable to adjust 
for confounding factors. There were a variety of parametric 
tests performed that assume normality, such as analysis of vari-
ance, analysis of covariance, and multivariable linear models, 
which can adjust for confounding factors. Other methods such 
as correlations and Student’s t-test were also used. However, 
applying these methods to MN data, which are rarely normally 
distributed, could result in inappropriate inferences. Although 
the data could be transformed to better adhere to a Gaussian 
distribution before applying such parametric tests, few studies 
applied any type of transformation. Further, Student’s t-tests 
and Pearson’s correlation cannot adjust for confounding vari-
ables. The common non-Gaussian models used were log-linear, 
Poisson, negative binomial, and logistic regressions. The logistic 
and log-linear models account for categories, whereas Poisson 
and negative binomial models directly model count data. For 
this reason, Ceppi et al.5 recommend using negative binomial 
or Poisson models for MN data analysis. Another advantage of 
these count models is that they can adjust for confounding vari-
ables such as age, gender, and smoking status. Finally, Ceppi 
et al.5 recommended that 2000 or more cells be scored for best 
model performance. If ,2000 cells are scored, a zero-inflated 
Poisson model is recommended.5
When trying to identify molecular features related to 
MN frequency, high-throughput genomic assays can be used. 
However, the previously described methods cannot be applied 
in settings wherein there are more predictor variables than 
samples. Therefore, in this study, we extended the generalized 
monotone incremental forward stagewise (GMIFS) method 
to the Poisson regression setting and applied it to a cord blood 
study, the MN frequency of which we were interested in pre-
dicting using features from the Agilent 4 × 44k human oligo-
nucleotide microarray.
Methods
Data. The cord blood data were collected as part of the 
Norwegian Mother and Child Cohort Study (MoBa).6 The 
target population of MoBa comprised all women who gave 
birth in Norway. The overall goal of this study was to collect 
data on pregnant women and their children to estimate the 
association between exposures and diseases. Specifically, the 
data are taken from a subcohort called BraMat, which trans-
lates to “good food” in English. This subcohort concentrates on 
what effect a pregnant woman’s diet has on her child. Umbili-
cal cord blood samples were collected immediately after birth 
from 200 babies. After quality control and other exclusions, 
111 samples were hybridized to Agilent 4 × 44k human oli-
gonucleotide microarrays to measure gene expression. Of the 
111 subjects, 29 also had MN data collected. The MNs were 
scored using the procedure described by Decordier et al.7 Fur-
ther, demographics such as gender, were collected for all sub-
jects. Data were downloaded from Gene Expression Omnibus 
(GSE31836). Sample processing, image analysis, normaliza-
tion, background correction, and filtering are described in the 
study by Hochstenbach et al.8 For this analysis, the data were 
further filtered to only include genes that had no missing val-
ues, leaving 8497 genes for statistical analysis.
Statistical methods. There are many available methods 
that can model count data. However, these methods require 
independence of explanatory variables (p) and that the number of 
samples (n) does not exceed the number of explanatory variables. 
The incremental forward stagewise regression method for linear 
regression and the GMIFS for a logistic regression model have 
been previously described.9 The GMIFS method for modeling 
ordinal response data has also been described.10 To assist in our 
extension to the Poisson regression setting, we first review Pois-
son regression. We subsequently describe our GMIFS method 
for fitting Poisson regression models when n , p.
Poisson regression. Poisson regression is commonly used 
to model count data. Let i = 1,…, n be the number of observa-
tions and yi represent a Poisson-distributed random variable. 
Let the expected value of yi be written as
 E yi i( ) = λ .
Then, the conditional probability is given by
 
P y yi i
i
y
i
i i| λ λ( ) = −e λ !
GMIFS poisson model for modeling count data
99CANCER INFORMATICS 2015:14(S2)
for each observation i. The likelihood is represented by
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y
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−
=
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Mathematically, it is easier to maximize the log-likelihood, 
which is given by
 
 λ | λ λy( ) = − − ( )( )
=
∑ y yi i i i
i
n
log log ! .
1
Thus, we are looking for the value of λ that maximizes the 
log-likelihood above. Further, an offset is used if the response 
variable can be considered a rate. For example, MN frequency 
is scored from a larger number of total cells. Therefore, if the 
total number of cells examined varies by subject, an offset is 
appropriate. In this case, the expected value is
 E y ti i i( ) = λ
where ti is the offset value. The conditional probability is then 
given by
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for each observation i. The likelihood is represented by
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Again, mathematically, it is easier to maximize the log- 
likelihood, which is given by
 
 λ | λ λy( ) = ( ) − − ( )( )
=
∑ y t t yi i i i i i
i
n
log log ! .
1
Once again, we are looking for the λ value that maximizes 
the log-likelihood. These log-likelihoods are used to model 
predictor variables. In Poisson regression, the model assumes 
that the expected value can be modeled by a linear combina-
tion of predictors. In this case, the natural log of ti is entered 
as an offset in the model estimation. The natural log of the 
expected value is
 
where xi is a vector of predictor variables and θ is a vector of 
coefficients. The estimated coefficients can be exponentiated 
to determine how the response changes with the predictor. By 
using the estimated linear combination of coefficient estimates 
and taking the exponent, we can calculate the estimated 
response of that particular subject.
GMIFS Poisson model. The GMIFS method was pre-
viously described for the logistic regression scenario by Hastie 
et al.9 but can be adapted to a Poisson regression model. For the 
proposed method, we consider three types of parameters that 
θ from the section “Poisson regression” can be separated into 
along with an offset (ti). The parameters are the intercept (α), 
those corresponding to an unpenalized subset of predictors (γ), 
and those corresponding to a set of penalized predictors (β). The 
design matrix, x, consists of two parts, xj and xk, where j = 1,…, J 
is the number of unpenalized predictors, k = 1,…, K is the set of 
penalized predictors, and J + K = P is the total number of predic-
tors. The unpenalized predictors are those that we wish to force 
into the model, such as gender, age, and smoking status, which 
researchers consider important predictors of MN frequency5 and 
their values are in the xij design matrix for subject i. The penal-
ized variables (thousands of features from a high-throughput 
genomic experiment) are those that the model will choose for 
us and are considered to be the investigative predictors and their 
values are in the xik design matrix for subject i.
The algorithm proceeds in an iterative fashion and updates 
one of the penalized covariates by a small incremental amount 
at each step. To determine which penalized covariate is to be 
updated next, the largest negative gradient is used. Thus, we 
need to calculate the first derivative of the log-likelihood cor-
responding to each penalized predictor. The log-likelihood 
written in terms of α, β, and γ is
and the first derivative written in terms of α, β, and γ  in matrix 
notation is
 
Once we know which covariate to update, we need to 
determine in what direction to update the covariate. To know 
the direction of the update, the second derivative would need 
to be calculated, which is a cumbersome process. Hastie et al.9 
showed that to avoid having to calculate the second deriva-
tive, an expanded covariate space can be used. For example, let 
β1,…, βp be the positive coefficient estimates and βp+1,…, β2p 
be the negative coefficient estimates. Then, the original esti-
mates are calculated by subtracting the pairs, β1 – βp+1,…, 
β2p – β2. Thus, using the notation mentioned previously, 
where xj are the unpenalized variables and xk are the vari-
ables in the penalized subset, the expanded covariate space is 
x x x x= − j k k: : . The proposed GMIFS algorithm using the expanded covariate set is
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1. Initialize the components of  at step s = 0.
2. Initialize the intercept α and the unpenalized coefficients 
γj where j = 1,…, J using a maximization algorithm of the 
log-likelihood.
3. Considering α and γ fixed, find the predictor xm where 
m l
K k
= −
∂
∂



argmin β  at the current estimate .
4. Update the corresponding coefficient β β ε m
s
m
s+( ) ( )
= +
1  to 
yield a new vector of parameter estimates.
5. Update α and the unpenalized coefficients, γj, by maxi-
mum likelihood considering the  from step 4 as 
fixed.
6. Repeat steps 3–5 until the difference between successive 
log-likelihoods is less than a prespecified tolerance, τ.
The defaults for the GMIFS algorithm are ε = 0.001 and 
τ = 0.00001.
Comparative method: penalized linear regression. 
A penalized linear regression model can be fit by adding a 
penalty term to the sums of squares. Specifically, the glmpath 
algorithm uses a linear combination of the L1 and L2 norm 
penalizations. The generalized linear model path (glmpath) 
algorithm is based on a previous algorithm called least absolute 
shrinkage and selection operator (LASSO). LASSO mini-
mizes the typical sum of squares with an added constraint. 
Specifically, for linear regression, LASSO minimizes11
 
y xi ij j
j
j
j
p
i
N
−



 +∑ ∑∑ == β β
2
11
λ | |
where xij are the standardized predictors and yi is the set of 
centered responses for i = 1,…, N and j = 1,…,p. Because of the 
form of the constraint, LASSO does both variable selection 
and shrinkage. The glmpath algorithm modifies this slightly 
by first considering the typical generalized linear model 
formula
 
where L denotes the appropriate likelihood function. The 
glmpath algorithm then adds an analagous LASSO penalty 
term to help with variable selection when p . n:
 
where λ .  0 is the regularization parameter. The glmpath 
algorithm computes coefficient estimates as λ varies. The 
algorithm starts with the largest λ that makes β λ( )  nonzero, 
with each step using a smaller λ. Each optimization consists 
of three parts: determining the step size in λ, predicting the 
corresponding change in the coefficients, and correcting the 
error in the previous prediction.12 The algorithm continues 
finding the next largest λ that will change the coefficient 
estimates until no further predictors can be found. However, 
when the predictors are strongly correlated, the coefficient 
estimates become highly unstable using the L1 norm penaliza-
tion.9 Thus, the glmpath algorithm adds a quadratic penalty 
term and computes the solution to
 
where λ1 ∈ (0, ∞) and λ2 is a fixed, small, positive constant. 
By adding this quadratic penalty, the effects of the strong cor-
relations do not affect the stability of the fit. Further, when the 
correlations are not strong, the effects of the quadratic penalty 
are neglible.9 Thus, the glmpath algorithm uses both the L1 
and L2 penalties as its default method.
The glmpath algorithm uses a default binomial distribu-
tion with a logit link and λ2 = 0.00001. The algorithm also 
allows for a Poisson distribution with a log link and Gaussian 
distribution with an identity link. The algorithm then com-
putes the regularization path for generalized linear models 
with L1 penalty.
Simulations. Simulations are a useful technique to test 
how well a new methodology performs. In this case, we wished 
to quantify how accurately the GMIFS method estimated true 
nonzero coefficients and predicted count data. Furthermore, 
we wished to determine how the GMIFS method compared 
relative to the glmpath method in predicting the count out-
come, and simulations provide a good platform to accomplish 
this comparison. Several general steps must be considered in 
the simulation process: how to simulate the response, how to 
simulate the predictors associated with the response, and how 
to simulate the predictors not associated with the response. 
Furthermore, we wished to examine how the methods per-
form under ideal situations and nonideal situations, such as 
when distributional assumptions are met and are not met, 
respectively. Note that all simulations were performed using 
the R programming environment (version 3.1.1).13
First, we considered the situation where the response 
is Poisson distributed and the user fits a Poisson regression 
model. Then, we generated the response to follow a Poisson 
distribution where an offset was either used or not used. The 
uniform distribution was used to generate the predictors. The 
steps involved in simulating the data under these conditions 
were as follows:
1. Randomly generate P variables, xi1, xi2,…, xiP where 
i = 1…n, using the uniform distribution on the [0,1] 
interval.
2. Choose P1 of the P variables to be associated with the 
response.
GMIFS poisson model for modeling count data
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the results of the simulations. Figure 1 shows the distribution 
of the number of predictors correctly identified as nonzero 
over 100 simulations and the types of models used. The data 
were generated using both n = 30 and n = 80 observations. The 
median number of correctly identified nonzero coefficients 
with no offset using GMIFS is 1 (range = 0, 3) for n = 30 and 
2 (range = 0, 4) for n = 80. Similarly, the median number of 
correctly identified nonzero coefficients with no offset using 
glmpath with Poisson family is 1 (range = 0, 5) for n = 30 and 
2 (range =  0, 4) for n =  80. This number increases slightly 
when using the glmpath with Gaussian family to a median 
of 2 (range = 0, 5) for n = 30 and 4 (range = 2, 5) for n = 80. 
All the numbers are similar when an offset is used to generate 
the data. The median number of correctly identified non-zero 
coefficients using GMIFS is 0 (range = 0, 3) for n = 30 and 
1 (range = 0, 4) for n = 80. The median number of correctly 
identified non-zero coefficients using glmpath with Poisson 
family is 0 (range = 0, 3) for n = 30 and 1 (range = 0, 4) for 
n = 80. Once again the medians increase when using the glm-
path with Gaussian family to 2 (range = 0, 5) for n = 30 and 4 
(range = 2, 5) for n = 80.
Figure  2  shows the distribution of the number of pre-
dictors incorrectly identified as nonzero over 100 simulations 
and the types of models used. The data were generated using 
both n = 30 and n = 80 observations. The median number of 
incorrectly identified nonzero coefficients with no offset using 
GMIFS is 3 (range = 0, 15) for n = 30 and 7 (range = 0, 28) for 
n = 80. Similarly, the median number of incorrectly identified 
nonzero coefficients with no offset using glmpath with Pois-
son family is 3 (range = 0, 17) for n = 30 and 7 (range = 0, 41) 
for n =  80. This number increases when using the glmpath 
with Gaussian family to a median of 26 (range = 23, 28) for 
n = 30 and 74 (range = 73, 76) for n = 80. All results are simi-
lar when an offset is used to generate the data. The median 
number of incorrectly identified non-zero coefficients using 
GMIFS is 2 (range = 0, 14) for n = 30 and 5 (range = 0, 26) for 
n = 80. The median number of incorrectly identified non-zero 
coefficients using glmpath with Poisson family is 2 (range = 0, 
24) for n = 30 and 4.5 (range = 0, 31) for n = 80. Once again 
the medians increase when using the glmpath with Gaussian 
family to 26 (range = 23, 28) for n = 30 and 74 (range = 72, 
76) for n = 80.
Figure 3 shows the distribution of the sum of residuals 
squared as a measure of the model prediction accuracy. The 
data were generated using both n = 30 and n = 80 observa-
tions. For both sample sizes, a learning data set was used to 
estimate coefficients and then the model was applied to an 
independent test data set. The median accuracy with no offset 
using GMIFS is 133 (range =  68, 240) for n =  30 and 325 
(range =  188, 699) for n =  80. Similarly, the median accu-
racy with no offset using glmpath with Poisson family is 142 
(range = 55, 254) for n = 30 and 333 (range = 185, 1666) for 
n =  80. The median accuracy with no offset using glmpath 
with Gaussian family is 206 (range = 90, 383) for n = 30 and 
3. Assign the P1 β values associated with the response and 
the intercept value, α. If the offset is to vary, then a uni-
form distribution was used with maximum 2200 and 
minimum 1800 and subsequently rounded to the near-
est integer. This range was selected because it is recom-
mended to score MNs using 2000 cells.
4. Generate the λ values for the Poisson distribution using 
the following formula:
 
λ α βi i k ik
k
P
t= + ( ) +

=∑exp log .x1
1
5. Randomly generate Yi ∼ Poisson(λi).
6. Fit a Poisson GMIFS model and fit a glmpath model.
7. Repeat steps 1–6 r times.
This simulation method was adjusted in several places. 
In this case, we chose n =  30 and n =  80. We studied the 
models letting P = 100 predictor variables and P1 = 5 predic-
tor variables associated with the response; r = 100 simulations 
were used. The intercept (α) and the five predictor variables 
associated with the response (β1, β2, β3, β4, and β5) were set to 
–5, 0.3, 0.2, –0.7, 0.5, and 0.1, respectively, for data simulated 
using no offset. For data simulated using an offset, α was set 
to –7. This was done to keep λ values low so that the Gaussian 
approximation for the Poisson distribution is not appropriate. 
To compare the two different statistical models, the following 
three outcomes were examined:
1. The number of true predictors that have a nonzero 
coefficient;
2. the number of false predictors that have a nonzero 
coefficient;
3. accuracy of count predictions from the model (sum of 
squared residuals) when applied to an independent test 
set.
The methods were compared with and without the use 
of an offset during the simulation process. Furthermore, the 
glmpath method allows for the use of Gaussian and Poisson 
distributions. Thus, those options were also used to see what 
effects user error had on the results. Thus, a total of three mod-
els were compared when the true distribution was Poisson:
1. Poisson GMIFS model;
2. glmpath using “poisson” family option and λ2 = 0 which 
fits a LASSO model; and
3. glmpath using “gaussian” family option and λ2 = 0 which 
fits a LASSO model.
Results
Simulations. Simulations were performed as described in 
“Simulations” of the Methods section, and Figures 1–3 show 
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Figure 1. Number of predictors correctly identified as nonzero. This figure shows the distribution of the number of predictors correctly identified as 
nonzero over 100 simulations. There were five predictors that were set as nonzero. Boxplots are separated by the type of distribution used to generate  
the data and the number of observations.
100
80
No offset n = 30
No offset n = 80
Offset n = 30
Offset n = 80
N
u
m
b
er
 p
re
d
ic
to
rs
 in
co
rr
ec
tl
y
id
en
ti
fi
ed
 a
s 
n
o
n
-z
er
o
60
40
20
0 0
G
M
IF
S
G
M
IF
S
G
M
IF
S
G
M
IF
S
gl
m
pa
th
gl
m
pa
th
gl
m
pa
th
gl
m
pa
th
gl
m
pa
th
G
au
ss
ia
n
gl
m
pa
th
G
au
ss
ia
n
gl
m
pa
th
G
au
ss
ia
n
gl
m
pa
th
G
au
ss
ia
n
Figure 2. Number of predictors incorrectly identified as nonzero. This figure shows the distribution of the number of predictors incorrectly identified as 
nonzero over 100 simulations. There were 95 predictors for which their coefficients were set to zero. Boxplots are separated by the type of distribution 
used to generate the data and the number of observations.
1503 (range = 535, 3772) for n = 80. The numbers are different 
when an offset is used to generate the data. The median accu-
racy using GMIFS is 80 (range = 30, 185) for n = 30 and 205 
(range = 137, 367) for n = 80. The median accuracy using glm-
path with Poisson family is 80 (range = 33, 805) for n = 30 and 
206 (range = 126, 339) for n = 80. The median accuracy with 
an offset using glmpath with Gaussian family for both sample 
sizes is above 50000.
Gene expression analysis. Both GMIFS and glmpath 
models were applied to the cord blood gene expression data set 
described under “Data” of Methods section. For glmpath, the 
Poisson family option was used and the lambda2 option was 
set to zero. For GMIFS, the default options were chosen. The 
response in the model was MN counts, and the predictors were 
the gene expression intensities. Gender was included in the 
model as part of the unpenalized subset. Based on Figure 4, a 
GMIFS poisson model for modeling count data
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Figure 3. Accuracy of count predictions. This figure shows the distribution of the sum of residuals squared over 100 simulations using a learning  
data set and an independent test data set. Boxplots are separated by the type of model fit to the data and the number of observations. The results for 
glmpath with Gaussian family using an offset are not displayed because both values are above 50000.
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Figure 5. Plot of actual MN counts versus predicted MN counts using 
GMIFS.
Poisson distribution was assumed for both models because the 
data appear skewed. The final model parameters were chosen 
using the minimum Akaike information criterion. The GMIFS 
model identified 17 nonzero gene expression coefficients as 
associated with MN count and the glmpath with Poisson fam-
ily identified 23. Out of the genes that were identified, 10 were 
common to both models. Figures  5 (sum of squared residu-
als = 101.7) and 6 (sum of squared residuals = 1.8) show that 
both models seem to predict MNs relatively well. Table 1 shows 
the genes that both models identified as being associated with 
MN count and the types of cancer with which they are linked. 
Nine out of the 10 genes in common between both models are 
linked to some type of cancer.
Discussion
We have described the GMIFS method for modeling a count 
response when we want to (1) coerce some variables into the 
model and (2) perform automatic variable selection and model 
estimation by penalizing predictors. High-throughput data 
contain more predictors than there are samples, so traditional 
methods are not appropriate in this setting. The GMIFS 
method was compared to glmpath, a popular penalization 
algorithm. Simulations showed that both methods performed 
similarly when identifying predictors known to be nonzero. 
GMIFS appeared to slightly outperform glmpath in the sense 
that GMIFS included fewer predictors that are truly unim-
portant in the model. Similarly, when applied to an indepen-
dent data set, GMIFS appeared to have higher predictive 
accuracy. Thus, it appears that GMIFS is more generalizable 
than glmpath to independent data sets.
Finally, both methods were applied to a cord blood 
gene expression data set. Gene expression profiles were used 
Makowski and Archer
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Table 1. Genes identified as associated with MN count by both GMIFS and glmpath.
PROBE ID GENE SYMBOL GENE NAME ASSOCIATED WITH CANCER GMIFS GLMPATH
A-23-P100196 USP10 ubiquitin specific peptidase 10 Glioblastoma multiforme14 X X
A-23-P138967 SDHD succinate dehydrogenase complex Tumor Suppressor15 X X
A-23-P42331 HMGA1 high mobility group AT-hook 1 Pancreatic Adenocarcinoma16 X X
A-23-P9293 TJP2 tight junction protein 2 Breast17 X X
A-24-P19410 CBX7 chromobox homolog 7 Carcinomas18 X X
A-24-P214858 TREML2 triggering receptor expressed on  
myeloid cells-like 2
Pancreatic19 X X
A-24-P2463 WHSC1 Wolf-Hirschhorn syndrome candidate 1 Carcinogenesis20 X X
A-24-P397584 TBCC tubulin folding cofactor C None Found X X
A-24-P398064 KIAA0258 KIAA0258 Colorectal21 X X
A-32-P18547 C21ORF57 chromosome 21 open reading frame 57 Breast22 X X
A-23-P103824 FAU Finkel-Biskis-Reilly murine sarcoma  
virus (FBR-MuSV) ubiquitously expressed
None Found X
A-23-P209394 CFLAR CASP8 and FADD-like apoptosis regulator Human cancers23 X
A-23-P79911 PSMF1 proteasome (prosome, macropain) inhibitor  
subunit 1 (PI31)
Breast24 X
A-24-P202567 ITPKC inositol 1,4,5-trisphosphate 3-kinase C Cervical25 X
A-24-P31235 EIF5A eukaryotic translation initiation factor 5A Chronic myeloid leukemia26 X
A-24-P405054 C1ORF144 chromosome 1 open reading frame 144 Mantle cell lymphoma27 X
A-32-P156549 C1ORF144 X
A-23-P118313 GABARAPL2 GABA(A) receptor-associated protein-like 2 Lung28 X
A-23-P143817 MYLK myosin, light polypeptide kinase Gastric29 X
A-23-P156809 LOC642880 similar to FKSG62 None Found X
A-23-P394304 PDZK1IP1 PDZK1 interacting protein 1 Thyroid30 X
A-23-P39665 SLC11A1 solute carrier family 11, member 1 Esophageal31 X
A-23-P67529 KCNN4 potassium intermediate/small conductance  
calcium-activated channel, subfamily N,  
member 4
Colorectal32 X
A-24-P594683 LOC645592 similar to peptidylprolyl isomerase  
A isoform 1
X
A-24-P708161 X
A-24-P98086 GNA12 guanine nucleotide binding protein  
(G protein) alpha 12
Oral33 X
A-32-P10067 X
A-32-P137849 X
A-32-P169754 LOC145221 EST X
A-32-P208078 MTHFR 5,10-methylenetetrahydrofolate reductase  
(NADPH)
Breast34 X
 
to predict MN frequency. Both models identified a similar 
number of genes as related to MN frequency. Further, 10 of 
those genes were common to both models. Nine out of the 
10 genes have been shown to be associated with different types 
of cancers. Because MN count is a measure of DNA damage, 
genes associated with MN frequency would be expected to be 
linked to cancer.
Both models appear to identify genes linked to cancer. As 
in the simulations, glmpath identified more genes as nonzero 
compared to GMIFS. In the simulations, this was because glm-
path was including more predictors incorrectly. However, there 
is no way to know whether this is also the case in the cord blood 
data set, given that these data are observational and no further 
confirmatory studies can be performed on the samples.
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Figure 6. Plot of actual MN counts versus predicted MN counts using 
glmpath.
